HIV Treatment and Prevention Agents Immunization Vaccines 
Pharmaceutical Technology
JUNE 11, 2025
The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipeline remains unaffected. Gilead is considered the leading big pharma in HIV treatments. Shares in Nasdaq-listed Gilead opened 0.3%
Pharmacy Times
JUNE 23, 2025
The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 16, 2025
Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents.
Pharmacy Times
JUNE 10, 2025
3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. 2 REFERENCES 1.
Pharmacy Times
JULY 3, 2025
Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)
PharmaShots
APRIL 25, 2023
This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M
Pharmacy Times
JULY 1, 2025
Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)
Expert insights. Personalized for you.
52 
Let's personalize your content